NO951861L - ECK-reseptorligander - Google Patents

ECK-reseptorligander

Info

Publication number
NO951861L
NO951861L NO951861A NO951861A NO951861L NO 951861 L NO951861 L NO 951861L NO 951861 A NO951861 A NO 951861A NO 951861 A NO951861 A NO 951861A NO 951861 L NO951861 L NO 951861L
Authority
NO
Norway
Prior art keywords
eck receptor
eck
receptor
receptor ligands
ligands
Prior art date
Application number
NO951861A
Other languages
English (en)
Norwegian (no)
Other versions
NO951861D0 (no
Inventor
Timothy D Bartley
William J Boyle
Gary M Fox
Andrew A Welcher
Vann P Parker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO951861D0 publication Critical patent/NO951861D0/no
Publication of NO951861L publication Critical patent/NO951861L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
NO951861A 1992-11-13 1995-05-11 ECK-reseptorligander NO951861L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97770892A 1992-11-13 1992-11-13
US14561693A 1993-11-09 1993-11-09
PCT/US1993/010879 WO1994011020A1 (en) 1992-11-13 1993-11-12 Eck receptor ligands

Publications (2)

Publication Number Publication Date
NO951861D0 NO951861D0 (no) 1995-05-11
NO951861L true NO951861L (no) 1995-07-11

Family

ID=26843152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951861A NO951861L (no) 1992-11-13 1995-05-11 ECK-reseptorligander

Country Status (14)

Country Link
US (2) US5650504A (xx)
EP (1) EP0597503B1 (xx)
JP (1) JPH08505765A (xx)
CN (1) CN1094446A (xx)
AT (1) ATE172246T1 (xx)
AU (1) AU685765B2 (xx)
CA (1) CA2149333C (xx)
DE (1) DE69321555T2 (xx)
DK (1) DK0597503T3 (xx)
ES (1) ES2121915T3 (xx)
FI (1) FI952328A (xx)
IL (1) IL107599A0 (xx)
NO (1) NO951861L (xx)
WO (1) WO1994011020A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2094134A1 (en) * 1990-10-16 1992-04-17 Vishva M. Dixit Cytokine-induced marker for inflammatory response
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
WO1994011384A1 (en) * 1992-11-13 1994-05-26 Immunex Corporation Novel cytokine designated elk ligand
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
ATE232901T1 (de) * 1994-04-04 2003-03-15 Regeneron Pharma Biologisch aktive ligande der eph familie
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
ATE263781T1 (de) * 1994-10-27 2004-04-15 Genentech Inc Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6100346A (en) * 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
DE69924009T2 (de) 1998-12-23 2006-04-13 Regeneron Pharmaceuticals, Inc. Methode zur verstärkung der biologischen aktivität von liganden
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
EP1870464A3 (en) * 1999-06-02 2008-03-12 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2002086460A1 (en) * 2001-04-20 2002-10-31 Consensus Pharmaceuticals, Inc. Methods for identifying ligands of g-protein-coupled receptors
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
EP1553963A4 (en) 2002-09-24 2006-05-03 Burnham Inst NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY
US7862816B2 (en) 2003-03-12 2011-01-04 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
CA2522082A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
EP1628992A4 (en) * 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic METHODS FOR MODULATING METASTASIS AND SKELETAL RELATED EVENTS RESULTING FROM METASTASES
EP1730196B1 (en) 2004-03-12 2010-12-22 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
CN101146822A (zh) 2005-01-27 2008-03-19 伯纳姆研究所 EphB受体结合肽
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001052A (nl) * 1990-05-02 1991-12-02 Tno Werkwijze voor het bepalen van een specifiek ligand in een vloeibaar monster met behulp van een evanescent veld, alsook een daarvoor geschikt onderdeel van de benodigde meetinrichting.
CA2094134A1 (en) * 1990-10-16 1992-04-17 Vishva M. Dixit Cytokine-induced marker for inflammatory response

Also Published As

Publication number Publication date
EP0597503A2 (en) 1994-05-18
US5650504A (en) 1997-07-22
ATE172246T1 (de) 1998-10-15
AU685765B2 (en) 1998-01-29
DE69321555D1 (de) 1998-11-19
CA2149333A1 (en) 1994-05-26
CA2149333C (en) 2002-01-22
IL107599A0 (en) 1994-02-27
ES2121915T3 (es) 1998-12-16
EP0597503A3 (en) 1995-05-24
WO1994011020A1 (en) 1994-05-26
FI952328A0 (fi) 1995-05-12
NO951861D0 (no) 1995-05-11
AU5599794A (en) 1994-06-08
FI952328A (fi) 1995-07-10
CN1094446A (zh) 1994-11-02
JPH08505765A (ja) 1996-06-25
EP0597503B1 (en) 1998-10-14
DK0597503T3 (da) 1999-06-23
US5716934A (en) 1998-02-10
DE69321555T2 (de) 1999-06-24

Similar Documents

Publication Publication Date Title
NO951861L (no) ECK-reseptorligander
WO1996036713A3 (en) Eck receptor ligands
DK446386A (da) Proteinhydrolysater, fremgangsmaader til fremstilling deraf og laegemidler, der indeholder disse hydrolysater
DK214090D0 (da) 5-aminosulfonylalkyl-indolderivater, fremgangsmaade og mellemprodukt til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK568487D0 (da) Norstatin- og norcyclostatinholdige polypeptider og farmaceutiske praeparater indeholdende disse.
DK164868C (da) Imidazooe4,5-baaquinolin-2-on-derivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK0927192T3 (da) Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
DK362787D0 (da) Benzensulfonamido-indanylforbindelser, laegemidler indeholdende disse forbindelser og fremgangsmaade til deres fremstilling
NO165966C (no) Fremgangsmaate for utvinning av chitin fra materialer hvorchitin opptrer sammen med, eller i tilknytning til, proteinsubstanser.
DK556689A (da) Antistof-konjugater, fremgangsmaade til fremstilling heraf og farmaceutiske midler indeholdende disse
NO904024D0 (no) Heparin-bindende proteiner, dna som koder for dem, fremgangsmaater for fremstilling derav og terapeutisk preparater inneholdende dem.
DK66086D0 (da) Dihydropyridiner, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DK92789A (da) Polypeptidderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DK494088A (da) 4-oxo-3-quinolincarboxylsyrer, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DK105886D0 (da) Monoklone anti-alfa-amylaseantistoffer, fremgangsmaade til fremstilling heraf samt laegemidler indeholdende disse antistoffer
DK165885D0 (da) Peptider, fremgangsmaade til fremstilling deraf, samt farmaceutiske praeparater, indeholdende disse peptider
DK191086D0 (da) Benzisoselenazolonylderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
NO161684C (no) Endoproteinase-lyste f or utvinning av enzymet, samt anvendelse av enzymet til sekvensbestemmelse av proteiner og peptider.
DK493988D0 (da) 4-oxo-3-quinolincarboxylsyrer, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse forbindelser
DK2488D0 (da) Dopamin-beta-hydroxylaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK65986A (da) Dihydropyridiner, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
NO872223D0 (no) Bakteriociner og preparater inneholdende disse for anti-virus behandling.
DK352586A (da) 11-methylen-aestr-15-ener, fremgangsmaader til deres fremstilling og farmaceutiske praeparater indeholdende disse aestrener
NO813974L (no) Bis-aminometyl-antrakinon-derivater, fremgangsmaate til deres fremstilling, midler inneholdende disse og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application